BC
ATRS

Broadfin Capital’s Antares Pharma, Inc. ATRS Stock Holding History

Broadfin Capital’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,336,700
Closed -$4.47M – 51
2019
Q3 		$4.47M Sell
1,336,700
-407,447
-23% -$1.34M 0.83% 32
2019
Q2 		$5.74M Sell
1,744,147
-899,800
-34% -$2.6M 1.25% 27
2019
Q1 		$8.01M Sell
2,643,947
-800,200
-23% -$2.59M 1.65% 25
2018
Q4 		$9.37M Sell
3,444,147
-1,179,100
-26% -$3.88M 1.23% 25
2018
Q3 		$15.5M Hold
4,623,247
– – 2.29% 14
2018
Q2 		$11.9M Sell
4,623,247
-50,000
-1% -$124K 1.88% 20
2018
Q1 		$10.3M Buy
4,673,247
+137,600
+3% +$310K 1.6% 21
2017
Q4 		$9.03M Buy
4,535,647
+1,329,747
+41% +$2.89M 1.48% 21
2017
Q3 		$10.4M Sell
3,205,900
-1,597,628
-33% -$4.93M 1.54% 19
2017
Q2 		$15.5M Sell
4,803,528
-2,838,678
-37% -$8.05M 1.88% 18
2017
Q1 		$21.7M Sell
7,642,206
-5,328,887
-41% -$12.8M 2.63% 11
2016
Q4 		$30.2M Sell
12,971,093
-1,914,300
-13% -$3.65M 3.36% 6
2016
Q3 		$25M Hold
14,885,393
– – 2.24% 12
2016
Q2 		$15.6M Sell
14,885,393
-200,000
-1% -$193K 1.52% 19
2016
Q1 		$13.1M Buy
15,085,393
+3,610,393
+31% +$3.49M 1.27% 24
2015
Q4 		$13.9M Buy
11,475,000
+3,000,000
+35% +$4.18M 0.85% 31
2015
Q3 		$14.4M Buy
8,475,000
+900,000
+12% +$1.76M 0.8% 31
2015
Q2 		$15.8M Buy
7,575,000
+2,875,000
+61% +$6.97M 0.85% 34
2015
Q1 		$12.7M Hold
4,700,000
– – 0.99% 26
2014
Q4 		$12.1M Buy
4,700,000
+1,000,000
+27% +$2.25M 1.05% 26
2014
Q3 		$6.77M Buy
3,700,000
+650,000
+21% +$1.42M 0.71% 41
2014
Q2 		$8.14M Buy
3,050,000
+750,000
+33% +$2.26M 0.79% 41
2014
Q1 		$8.05M Buy
2,300,000
+1,500,000
+188% +$6.66M 0.78% 41
2013
Q4 		$3.58M Buy
+800,000
New +$3.26M 0.47% 45

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Broadfin Capital's ATRS Position: Q4 2019 in Review

Broadfin Capital sold out of Antares Pharma, Inc. (ATRS) in Q4 2019, closing a stake of 1,336,700 shares — an estimated $4.47M sold.

Broadfin Capital first reported a position in ATRS in Q4 2013 and held it in 24 quarters. The position peaked at $30.2M in Q4 2016. 160 funds tracked by Wall St. Rank hold ATRS as of Q4 2019.

  • Broadfin Capital reported no remaining Antares Pharma, Inc. position as of Q4 2019 after selling out during the quarter.
  • Broadfin Capital sold 1,336,700 Antares Pharma, Inc. shares in Q4 2019, an estimated $4.47M.
  • Broadfin Capital first reported a position in Antares Pharma, Inc. in Q4 2013 and held it in 24 quarters.
  • Broadfin Capital's Antares Pharma, Inc. position peaked at $30.2M in Q4 2016.
  • 160 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.